Association of HLA class II allele and haplotype frequencies with chronic myelogenous leukemia and age-at-onset of the disease

Pathology and Oncology Research

Volumn 13, Issue 1, 2007, Pages 47-51

  Amirzargar, Ali Akbar ^a   Khosravi, Farideh ^a   Dianat, S Saied ^a   Alimoghadam, Kamran ^b   Ghavamzadeh, Fereidoun ^b   Ansaripour, Bita ^a   Moradi, Batool ^a   Nikbin, Behrooz ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Chrome myelogenous leukemia; Genetic susceptibility; HLA DQA1; HLA DQB1; HLA DRB

Indexed keywords

HLA ANTIGEN CLASS 2; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN;

ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; HAPLOTYPE; HLA TYPING; HOMOZYGOSITY; HUMAN; MALE; ONSET AGE; POLYMERASE CHAIN REACTION; PREVALENCE;

EID: 34249981152     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02893440     Document Type: Article

References (16)

1. Amirzargar A, Mytilineos J, Farjadian S, et al: Human leukocyte antigen class II allele frequencies and haplotype association in Iranian normal population. Hum Immunol 62:1234-1238, 2001
2. Bortin MM, D'Amaro J, Bach FH, et al: HLA associations with leukemia. Blood 70: 227-232, 1987
3. ten Bosch GJA, Toornvliet AC, Friede T, et al: Recognition of peptides corresponding to the joining region of p210BCR-ABL protein by human T cells. Leukemia 9: 1344-1348, 1995
4. Caruso C, Lo Campo P, Botindari C, Modica MA: HLA antigens in Sicilian patients affected by chronic myelogenous leukaemia. J Immunogenet 14: 295-299, 1987
5. Dorak MT, Chalmers EA, Gaffney D, et al: Human major histocompatibility complex contains several leukemia susceptibility genes. Leuk Lymphoma 12: 211-222, 1994
6. Haldane JB: The estimation and significance of the logarithm of a ratio of frequency. Ann Hum Genet 20:309-311, 1956
7. Kurzrock R, Kantarjian HM, Druker BJ, et al: Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med 138: 819-830, 2003
8. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215, 1988
9. Mundhada S, Luthra R, Cano P: Association of HLA Class I and Class II genes with bcr-abl transcripts in leukemia patients with t(9;22) (q34;q11). BMC Cancer 4: 25, 2004
10. Oguz FS, Kalayoglu S, Diler AS, et al: HLA system affects the age-at-onset in chronic myeloid leukemia. Am J Hematol 73: 256-262, 2003
11. Olerup O, Zetterquist H: HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 39: 225-235, 1992
12. Pawelec G, Max H, Halder T, et al: BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors. Blood 88: 211-218, 1996
13. Posthuma EFM, Falkenburg JHF, Apperley JF, et al: HLA-DR4 is associated with a diminished risk of the development of chronic myeloid leukemia (CML). Leukemia 14: 859-862, 2000
14. Tian H, Zhou SY, Liu ZH, et al: Association of HLA-DPB1 alleles with chronic myelogenous leukemia in southern Chinese Hans. Zhongguo Shi Yan Xue Ye Xue Za Zhi 11: 266-268, 2003
15. Yasukawa M, Ohminami H, Kojima K, et al: Analysis of HLA-DRB1 alleles in Japanese patients with chronic myelogenous leukemia. Am J Hematol 63: 99-101, 2000
16. Yotnda P, Firat H, Garcia-Pons F, et al: Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest 101: 2290-2296, 1998